RPID

0.73500.04%
KD

Kirk D. Malloy

Independent Chairman of Board

Dr. Kirk D. Malloy, Ph.D., serves as Independent Director at Araceli Biosciences Inc. He serves as Independent Chairman of Board of Rapid Micro Biosystems, Inc. since July 2023. He is Strategic Advisor at Vivid Genomics, Inc. He is Member of Advisory Board of Arboretum Ventures LLC. He founded BioAdvisors, LLC in April 2016 and serves as its Chief Executive Officer and Principal. Dr. Malloy served as Chief Executive Officer and President of Verogen, Inc., a sequencing company solely dedicated to forensic science from August 2017 to August 2018. He served as Senior Vice President & General Manager of Life Sciences and Applied Markets at Illumina Inc., from January 2014 to April 2016. Dr. Malloy oversees the Illumina's core platform technologies and the core markets they enable including complex diseases, agrigenomics, microbiology and metagenomics. He served as a Vice President of Customer Solutions of Illumina Inc. since May 12, 2005, where he was responsible for worldwide customer service, field applications support and quality assurance operations. At Illumina he was Vice President, Global Customer Solutions from May 2005 to December 2013, Vice President, Global Quality from December 2005 to May 2007 and Senior Director and Global Customer Solutions from 2002 to 2005. He served as Independent Director at DermTech, Inc. since July 18, 2022. As Chairman of the board of directors of Tagomics, Ltd., a cancer diagnostics company and is a director for several private genomics tools companies. His previous experience includes a several year career at Illumina, Inc. He also served as Vice President of Quality, building and leading the commercial support organization and a robust service business for all of Illumina's markets. Before Illumina, he held various commercial leadership positions at Biosite Diagnostics and QIAGEN Incorporated. Dr. Malloy is a senior healthcare executive with more than several years of leadership in life science tools, applied markets and molecular diagnostics. Dr. Malloy joined Illumina in 2002 as Senior Director of Customer Solutions and later added quality assurance to his responsibilities. Prior to Illumina, he was Director of Technical Service and Implementation at Biosite, Inc., where he was responsible for technical support, branding and provision of validation and compliance services for point-of-care diagnostics customers. Dr. Malloy served at Qiagen, Inc. as Customer Operations Manager. He has been an Independent Director of NS Wind Down Co., Inc. (formerly known as NanoString Technologies, Inc.) since September 12, 2016. He serves as a Director of Phoseon Technologies, JumpCode Genomics, Edico Genome, IGenomX and Agilome. He served as an Independent Chairman at Organovo Holdings, Inc. since August 2017 until September 15, 2020. He served as a Director of Organovo Holdings, Inc. since December 08, 2014, until September 15, 2020 and served as its Lead Independent Director from August 2016 to August 2017. He held various research and teaching positions at Northeastern University and Boston University. He is also an associate of Growth Source Inc. where he provides strategic consulting services. He completed a certification for Corporate Directors at UCLA Anderson School in 2012. Dr. Malloy received a BS in biology and Marine Science from the University of Miami, College of Arts & Sciences and his MS and Ph.D. degrees in marine biology/biochemistry from the University of Delaware.

公司職務